Search hospitals > Oklahoma > Oklahoma City
Oklahoma Medical Research Foundation
Claim this profileOklahoma City, Oklahoma 73104
Global Leader in Systemic Lupus Erythematosus
Global Leader in Lupus
Conducts research for Multiple Sclerosis
Conducts research for Coronary Artery Disease
Conducts research for Rheumatoid Arthritis
154 reported clinical trials
6 medical researchers
Summary
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 124 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.Area of expertise
1Systemic Lupus Erythematosus
Global LeaderANA positive
anti-dsDNA positive
anti-Sm positive
2Lupus
Global LeaderANA positive
anti-dsDNA positive
anti-Smith positive
Top PIs
Gabriel PardoOklahoma Medical Research Foundation6 years of reported clinical research
Studies Multiple Sclerosis
Studies Relapse
9 reported clinical trials
17 drugs studied
Cristina Arriens, MD, MSCSOklahoma Medical Research Foundation7 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Cutaneous Lupus Erythematosus
4 reported clinical trials
8 drugs studied
Judith A. James, MD, PhDOklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program7 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Coronavirus
2 reported clinical trials
5 drugs studied
Christina Arriens, MDOklahoma Medical Research Foundation3 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Lupus
2 reported clinical trials
7 drugs studied
Clinical Trials running at Oklahoma Medical Research Foundation
Systemic Lupus Erythematosus
Lupus
Multiple Sclerosis
Lupus Nephritis
Critical Illness
Muscle Weakness
Sarcopenia
Antiphospholipid Syndrome
Relapse
Acquired Weakness
Shingles Vaccine
for Lupus
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials.
Recruiting2 awards Phase 4
Upadacitinib
for Lupus
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Recruiting1 award Phase 310 criteria
Pregnancy Outcomes
for Lupus and Antiphospholipid Syndrome
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Oklahoma Medical Research Foundation?
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 124 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.